Corrigendum to: EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol (Molecular Oncology, (2013), 7, 1, (121-129), 10.1016/j.molonc.2012.10.001);EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol

Molecular Oncology

Volumn 7, Issue 1, 2013, Pages 121-129

  Jeong, Kang Jin ^a   Cho, Kyung Hwa ^a   Panupinthu, Nattapon ^b   Kim, Hoon ^a   Kang, Jaeku ^a   Park, Chang Gyo ^a   Mills, Gordon B ^b   Lee, Hoi Young ^a  

^a Konyang University   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EGFR; Invasion; Lysophosphatidic acid; Ovarian cancer; Resveratrol

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE B; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; RAS PROTEIN; RHO KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME RELEASE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84872497453     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1002/1878-0261.12495     Document Type: Erratum

References (32)

1. Azios N.G., Dharmawardhane S.F. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 2005, 7:128-140.
2. Bese T., Barbaros M., Baykara E., Guralp O., Cengiz S., Demirkiran F., Sanioglu C., Arvas M. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J. Gynecol. Oncol. 2010, 21:248-254.
3. Cowden Dahl K.D., Zeineldin R., Hudson L.G. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol. Cancer Res. 2007, 5:413-421.
4. Dolo V., Adobati E., Canevari S., Picone M.A., Vittorelli M.L. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin. Exp. Metastasis 1995, 13:277-286.
5. Dutta S., Wang F.Q., Wu H.S., Mukherjee T.J., Fishman D.A. The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol. Oncol. 2011, 123:129-137.
6. Fang X., Schummer M., Mao M., Yu S., Tabassam F.H., Swaby R., Hasegawa Y., Tanyi J.L., LaPushin R., Eder A., Jaffe R., Erickson J., Mills G.B. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 2002, 1582:257-264.
7. Gardner M.J., Jones L.M., Catterall J.B., Turner G.A. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett. 1995, 91:229-234.
8. Gohla A., Harhammer R., Schultz G. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J. Biol. Chem. 1998, 273:4653-4659.
9. Horiuchi A., Kikuchi N., Osada R., Wang C., Hayashi A., Nikaido T., Konishi I. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci. 2008, 99:2532-2539.
10. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
11. Jeong K.J., Park S.Y., Cho K.H., Sohn J.S., Lee J., Kim Y.K., Kang J., Park C.G., Han J.W., Lee H.Y. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012, 31:4279-4289.
12. Jeong K.J., Park S.Y., Seo J.H., Lee K.B., Choi W.S., Han J.W., Kang J.K., Park C.G., Kim Y.K., Lee H.Y. Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp. Mol. Med. 2008, 40:607-616.
13. Lee J., Park S.Y., Lee E.K., Park C.G., Chung H.C., Rha S.Y., Kim Y.K., Bae G.U., Kim B.K., Han J.W., Lee H.Y. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin. Cancer Res. 2006, 12:6351-6358.
14. Mahabeleshwar G.H., Das R., Kundu G.C. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 2004, 279:9733-9742.
15. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3:582-591.
16. Murakami M., Shiraishi A., Tabata K., Fujita N. Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2008, 371:707-712.
17. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., Romero I.L., Carey M.S., Mills G.B., Hotamisligil G.S., Yamada S.D., Peter M.E., Gwin K., Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17:1498-1503.
18. Noguchi K., Herr D., Mutoh T., Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 2009, 9:15-23.
19. Oyesanya R.A., Greenbaum S., Dang D., Lee Z., Mukherjee A., Wu J., Dent P., Fang X. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Mol. Cancer 2010, 9:8.
20. Ozols R.F., Bookman M.A., Connolly D.C., Daly M.B., Godwin A.K., Schilder R.J., Xu X., Hamilton T.C. Focus on epithelial ovarian cancer. Cancer Cell 2004, 5:19-24.
21. Park S.Y., Jeong K.J., Lee J., Yoon D.S., Choi W.S., Kim Y.K., Han J.W., Kim Y.M., Kim B.K., Lee H.Y. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 2007, 258:63-69.
22. Park S.Y., Jeong K.J., Panupinthu N., Yu S., Lee J., Han J.W., Kim J.M., Lee J.S., Kang J., Park C.G., Mills G.B., Lee H.Y. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 2011, 30:1351-1359.
23. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
24. Sheng Q., Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 2011, 104:1241-1245.
25. Shida D., Fang X., Kordula T., Takabe K., Lepine S., Alvarez S.E., Milstien S., Spiegel S. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008, 68:6569-6577.
26. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
27. Simon C., Juarez J., Nicolson G.L., Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res. 1996, 56:5369-5374.
28. Snider A.J., Zhang Z., Xie Y., Meier K.E. Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation. Am. J. Physiol. Cell. Physiol. 2010, 298:C163-C170.
29. Sriwai W., Zhou H., Murthy K.S. G(q)-dependent signalling by the lysophosphatidic acid receptor LPA(3) in gastric smooth muscle: reciprocal regulation of MYPT1 phosphorylation by Rho kinase and cAMP-independent PKA. Biochem. J. 2008, 411:543-551.
30. Tabata K., Baba K., Shiraishi A., Ito M., Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 2007, 363:861-866.
31. Xu Y., Shen Z., Wiper D.W., Wu M., Morton R.E., Elson P., Kennedy A.W., Belinson J., Markman M., Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280:719-723.
32. Yance D.R., Sagar S.M. Targeting angiogenesis with integrative cancer therapies. Integr. Canc. Ther. 2006, 5:9-29.